|Dr. Giovanni Caforio M.D.||Chairman & CEO||5.82M||N/A||1965|
|Mr. David V. Elkins||Exec. VP & CFO||3.18M||1.3M||1968|
|Ms. Sandra Leung Esq.||Exec. VP & Gen. Counsel||2.73M||N/A||1961|
|Dr. Christopher S. Boerner||Exec. VP & Chief Commercialization Officer||2.61M||N/A||1971|
|Mr. Rupert Vessey BCH, BM, DPHIL, M.A.||Exec. VP and Pres of Research & Early Devel.||3.21M||1.45M||1965|
|Mr. Greg Meyers||Exec. VP and Chief Digital & Technology Officer||N/A||N/A||1973|
|Mr. Timothy Power||VP & Head of Investor Relations||N/A||N/A||N/A|
|Ms. Cari Gallman||Sr. VP & Chief Compliance and Ethics Officer||N/A||N/A||N/A|
|Ms. Ann M. Powell Judge||Exec. VP & Chief HR Officer||N/A||N/A||1966|
|Mr. Jitendra Tyagi||Head of US Drug Makers - India||N/A||N/A||N/A|
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Bristol-Myers Squibb Company’s ISS governance QualityScore as of 28 November 2022 is 2. The pillar scores are Audit: 8; Board: 5; Shareholder rights: 3; Compensation: 1.